

## Efficacy of *Geru* (red ochre) in controlling the bleeding in patients of Adolescent menorrhagia

Tabassum Kotagasti

Department of *Ilmul Qabalat wa Amaraze Niswan (OBG)*, National Institute of Unani Medicine, Kottige palya, India

### ABSTRACT

Adolescent menorrhagia is defined as excessive menstrual bleeding from menarche to adolescents. It is a distressing condition both for the patient as well as for her parents. If it is not managed in time it may pose significant health problems that may lead to blood transfusion. We determined the efficacy of *Geru* (Red ochre) in controlling the amount and duration of blood flow in patients of Adolescent menorrhagia. This study included 40 teenage girls, who presented with heavy bleeding during menstruation to Outpatient Department, Sameena Maternity Nursing Home, Hyderabad during the year of 2013. Assessment of each case was done by history and Pictorial Blood loss Assessment Chart (PBAC) score. *Geru* powder was given for 2 cycles and results were assessed. The data was analyzed statistically. The mean PBAC score before treatment was  $497.04 \pm 389.92$  and after trial in 1<sup>st</sup> and 2<sup>nd</sup> it was found to be  $471.13 \pm 162.18$  and  $310.13 \pm 142.15$  respectively. On basis of results it was concluded that single unani drug *Geru* is enough in controlling bleeding and was found effective by its astringent and styptic properties.

**Keywords** Adolescent menorrhagia, pictorial blood loss assessment chart score, efficacy, single drug, *Geru*

### INTRODUCTION

Gynecological problems of adolescents occupy a special place in the spectrum of gynecological disorder of all age groups especially puberty menorrhagia. Adolescent or Puberty menorrhagia is defined as excessive bleeding in amount more than 80ml or in duration more than 7 days between menarche and 19 years of age (Caufriez A, 1991; Hallberg et al., 1966). The prevalence of Adolescent menorrhagia is estimated about 75% of all adolescent problems. Almost a quarter of population in developing countries comprises girls below 20 years of age. In India; children less than 15 years of age constitute about 40% of population (Park, 2022). Menstrual disorders affect 75% of adolescent females and are a leading reason for visit to physicians (Gail, 2003). During this period, it is common for adolescents to present with complaints of menstrual irregularities. The onset of menstruation is influenced by a number of factors like genetics, nutrition, body weight and maturation of the hypothalamic pituitary ovarian axis. The onset of menstruation does not mean that ovulation is occurring. In the majority, early menstrual cycles are anovulatory (Lemarchand-Béraud et al., 1982). The cycle length varies for some considerable years after menarche. It may take some 5-8 years to establish regular menstrual cycle. During this time it is common for adolescents to present with menstrual irregularities (Hallberg et al. 1966; Lemarchand-Béraud et al., 1982). The most common cause of Adolescent menorrhagia is anovulatory

cycles, which are related to immaturity of the hypothalamic-pituitary-ovarian axis (Claessens and Cowell, 1981; Falcone et al., 1994).

There is an immaturity of the hypothalamus and negative feedback results in sustained high levels of oestrogen. An organic disease or malignancy in particular, is very rare. Heavy, irregular menstrual bleeding is a frequent complaint in adolescent girls. The prevalence of menorrhagia in adolescent populations with bleeding disorders varies between 14 to 48%. It is likely to be caused by mechanisms which are different from those which occur in women in the fourth or fifth decades of their life, where anatomic causes of bleeding are common (Bevan et al., 2001; Brenner, 1996; Hickey and Balen, 2003; Rao et al., 2004; Roychowdhury et al., 2008).

Anemia is a potential sequel of Adolescent menorrhagia (Revel-Vilk et al., 2012). This sequel may be prevented with appropriate management of the underlying problem. Therefore, it is important to establish the correct diagnosis before any therapy is administered. In conventional medicine the interventions used to reduce menstrual blood flow are by using hormones like combined oral Contraceptive (COC) pills, Gonadotrophin-Releasing Hormone (GnRH) analogues and oral progesterone.

In unani system of medicine in almost all classical text causes, clinical features, complications and treatment of menorrhagia are mentioned, but particular mention about puberty menorrhagia is not made. According to unani physicians the causes of menorrhagia are *sue mizaj rehm wa badan* (abnormal temperament of uterus or body), *Amraz rehm* (uterine diseases), *galbae-khilt safra* (dominance of bilious humour), *Imtilae badan* (plethora of body) *riqqat* and *latafat khoon* (liquefaction of blood) etc. According to Avicenna *zoafe quwat masika* (weakness in retentive faculty) and *Qawi Quwat Dafiya* (strong expulsive faculty) lead to this disease. If not treated in time, the disease leads to complication like anaemia,

\*Correspondence: Tabassum Kotagasti

E-mail: drtabassum.nium@gmail.com

Received January 15, 2015; Accepted May 21, 2015; Published May 31, 2015

doi: <http://dx.doi.org/10.5667/tang.2015.0002>

© 2015 by Association of Humanitas Medicine

This is an open access article under the CC BY-NC license.

(<http://creativecommons.org/licenses/by-nc/3.0/>)

as anaemia itself is a major health problem. Hence, treatment is necessary. In the Unani system of medicine number of drugs are mentioned for the treatment of menorrhagia for oral use in the form of powder, syrup or majoon etc., which are having the properties of *Habis*, *Qabiz* and *Muqawi*. These drugs decrease the menstrual blood flow by their specific properties.

Menorrhagia may be due to *zoafe quwat masika* (weakness in retentive faculty) and *Qawi Quwat Dafiya* (strong expulsive faculty) or *Sue Mizaj Haar* (Ill hot temperament). Accordingly temperament of these drugs is cold and dry. By virtue of their astringent, styptic properties and by their cold temperament they constrict the blood vessels and make the blood more viscous, hence control the bleeding.

There is poor correlation between a woman's perception of heavy menstrual bleeding and menstrual blood loss of more than or equal to 80 ml and between the number of sanitary pads used and the complaint of heavy bleeding (Janssen et al., 1995). Hence Pictorial Blood Loss Assessment Chart (PBAC) was used for the assessment of the results. The objective of the study was to evaluate the effect of *Geru* on excessive menstrual blood flow in patients of Adolescent menorrhagia on the basis of pictorial blood loss assessment scoring system.

## MATERIALS AND METHODS

The present clinical study was carried out in Outpatient Department, Sameena Maternity Nursing Home, Hyderabad during the year of 2013. The study population comprised of 40 teenage girls from 13 to 19 years of age with history of prolonged/heavy bleeding during menstruation. The detailed history regarding the age, age at menarche, duration of cycle, duration of flow, amount of flow, passing clots, number of pads required daily and pain abdomen were recorded. Assessment of blood loss during menstruation was estimated by taking detailed history of using sanitary pads per day.

Regarding the assessment of blood flow patients were given a pictorial blood loss assessment chart (PBAC) along with verbal instructions on how to fill the chart. PBAC is a simple scoring system. It takes into account the number of sanitary pads used per day and the degree of their soiling. The pictorial assessment chart was scored before and after trial as described by Higham et al (1990). The cutoff point 180 was most appropriate for diagnosing the menorrhagia, in this study cases with PBAC score of more than 400 were included and treated. Results were analyzed statistically.

**Design:** Before and after treatment

**Sample size:** 40 unmarried girls

**Inclusion criteria:** 13 - 19 years with prolonged or heavy blood flow

**Test drug:** *Geru* in the form of powder

**Duration of treatment:** For 3 days starting from 1<sup>st</sup> day of cycle, 3 gm of powder for oral use with water twice a day for 2 consecutive cycles

**Assessment of results:** By relief of symptoms and PBAC Score

## RESULTS AND DISCUSSION

The drug *Geru* is a mineral, a type of ore that is extremely high in iron content (70%) and its temperament is cold and dry. It is usually soft and fine-grained and is in use for controlling the bleeding in single or in combination with other drugs in case of haematemesis, epistaxis, menorrhagia, DUB of varied etiology since long, especially if bleeding is due to *hiddat*. Its *qabiz*

(astringent), *habisuddam* (styptic) and *mujaffif* properties are mentioned in all unani texts and several physicians have recommended its use in bleeding conditions.

Studies have been carried out on different astringent and styptic drugs like *Geru*, *Gulnaar*, *Sangjerahat*, *Dammul Akhwain*, *Teen ahmer*, *raal safed*, *Aab bartang* and *Samag Arabietcin* different combinations for their effect on controlling bleeding. A standard control clinical trial has been carried out on *safoof habis* in menorrhagia shown significant reduction in menstrual blood loss and the p value was reported as < 0.001 (Fathima and sultana, 2012). Another study on puberty menorrhagia with *safoof habisuddam* shown good response and the p value was same i.e. < 0.001 (Ram et al., 2013). A standard control clinical study on DUB with unani formulation containing *Geru* also showed good response. These studies have already confirmed the safety and the haemostatic properties of these drugs.

In this study total 40 adolescent girls were treated with single drug *Geru* powder. Out of 40 patients of Adolescent menorrhagia 16 (40%) cases had heavy blood flow, amounting to approximately more than 460 ml; whereas in the remaining 24 cases (60%), there was moderate loss of blood of more than 200 ml. Dysmenorrhoea was an associated complaint in 10 (25%) cases. Before trial the mean PBAC score was  $497.04 \pm 389.92$  and after trial in 1<sup>st</sup>, 2<sup>nd</sup> cycle it was found to be  $471.13 \pm 162.18$  and  $310.13 \pm 142.15$  respectively. Three gram of powder of *Geru* was given to all the patients for two cycles and the effect was assessed by PBAC score. The cutoff point of PBAC score was taken as 180 for effect. The results were as out of 40 patients 28 (70%) got good response and 9 (22.5%) got partial response and 3 (7.5%) patients had no response (Fig. 1). It indicates the astringent and potent styptic activity of single unani drug *Geru* (Red ochre) in controlling heavy menstrual blood flow and also in reducing its duration. It may be prescribed as first line therapy for this purpose and patient can be saved from unnecessary exposure to conventional hormonal therapy.




Fig. 1. Shows response of the drug.

## CONCLUSION

It was concluded that Adolescent menorrhagia is a common disorder among teenage girls. It is a major problem that poses severe health consequences requiring blood transfusion. Medical management is effective in most of the cases. Unani drug *Geru* was found to be effective in controlling heavy menstrual blood flow and in improving general condition. It is also concluded that single drug *Geru* can effectively be used for

controlling bleeding instead of combination of multiple drugs or hormonal treatment.

## ACKNOWLEDGEMENTS

None

## CONFLICT OF INTEREST

The authors have no conflicting financial interests

## REFERENCES

Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP. Bleeding disorders: A common cause of menorrhagia in adolescents. *J Pediatr*. 2001; 38:856-861.

Brenner PF. Differential diagnosis of abnormal uterine bleeding. *Am J ObstetGynaecol*. 1996; 175:766-769.

Caufriez A. Menstrual disorders in adolescence: pathophysiology and treatment. *Horm Res*. 1991; 36:156-159.

Claessens EA, Cowell CA. Acute adolescent menorrhagia. *Am J Obstet Gynecol*. 1981;139:277-280.

Falcone T, Desjardins C, Bourque J, Granger L, Hemmings R, Quiros E. Dysfunctional uterine bleeding in adolescents. *J Reprod Med*. 1994;39:761-764.

Fathima A, Sultana A. Clinical efficacy of a Unani formulation 'SafoofHabis' in menorrhagia: A randomized controlled trial. *Eur J Integr Med*. 2012;4:315-322.

Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss- a population study: variation at different ages and attempts to define normality. *ActaObstetGynecol*

*Scand*.1966;45:320-351.

Hickey M, Balen A. Menstrual disorders in adolescence: investigation and management. *Hum Reprod Update*.2003;9:493-504.

Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. *Br J ObstetGynaecol*. 1990;97:734-739.

Janssen CA, Scholten PC, Heintz APA. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. *ObstetGynecol*. 1995;85:977-982.

Lemarchand-Béraud T, Zufferey MM, Reymond M, Rey I. Maturation of the hypothalamo-pituitary-ovarian axis in adolescent girls. *J Clin EndocrinolMetab*. 1982;54:241-246.

Park K. Preventive Medicine in Obstetrics, Pediatrics and Geriatrics. In *Text Book of Preventive and Social Medicine*. Park K<sup>ed</sup>. (Jabalpur, India; Banarsidas and Bhanot), pp. 359-411, 2002.

Ram Singh, Tabassum, Shameem I, efficacy of Safoof Habisuddam on duration of flow in puberty menorrhagia, *Hippocratic J Unani Med*. 2013;8:23-29.

Rao S, Pawar V, Badhwar VR, Fonseca MN. Medical interventions in puberty Menorrhagia. *Br Med J*. 2004;328:921.

Revel-Vilk S, Paltiel O, Lipschuetz M, Ilan U, Hyam E, Shai E, Varon D, Revel A. Underdiagnosed menorrhagia in adolescents is associated with underdiagnosed anemia. *J Pediatr*. 2012;160:468-472.

Roychowdhury J, Choudhuri S, Sarkar A, Biswas PK. A study on the evaluation of the aetiological factors and the management of puberty menorrhagia. *Online J Health Allied Scs*. 2008;7:1-6.